Show simple item record

dc.contributor.authorPluchino, Stefanoen
dc.contributor.authorBernstock, Joshuaen
dc.contributor.authorGessler, Florianen
dc.contributor.authorPeruzzotti Jametti, Lucaen
dc.date.accessioned2018-02-16T16:50:00Z
dc.date.available2018-02-16T16:50:00Z
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/273310
dc.description.abstractGlioblastoma (GBM) is the most aggressive primary brain tumor and thrives in a microenvironment of relative immunosuppression. The poor clinical outcome of these malignant tumors requires the development of novel treatment options/therapeutic regimens. Accordingly, numerous immunotherapies for GBM are currently being tested in ongoing clinical trials. Herein we have examined the ability of the FDA approved drug topotecan to suppress programmed death-ligand 1 (PD-L1) expression. Our results suggest a role for topotecan as an adjuvant therapy in treatment regimens targeting certain GBM patient subpopulations in whom the expression of PD-L1 has been confirmed.
dc.description.sponsorshipThis research was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke/National Institutes of Health (NINDS/NIH).
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectStemCellInstituteen
dc.titleTopotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapyen
dc.typeArticle
prism.publicationNameMattersen
dc.identifier.doi10.17863/CAM.20334
dcterms.dateAccepted2017-10-05en
rioxxterms.versionVoR*
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2017-10-05en
dc.contributor.orcidPluchino, Stefano [0000-0002-6267-9472]
dc.contributor.orcidBernstock, Joshua [0000-0002-7814-3867]
dc.contributor.orcidGessler, Florian [0000-0002-3471-0575]
dc.contributor.orcidPeruzzotti Jametti, Luca [0000-0002-9396-5607]
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2017-10-05en


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International